4 marzo 2008 / 20:41 / tra 10 anni

Teva sues FDA on generic version of J&J's schizophrenia drug

March 4 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.O(TEVA.TA) said its U.S. unit filed a lawsuit against the U.S. Food and Drug Administration seeking 180-day exclusivity for the Israeli company’s generic version of Johnson and Johnson’s (JNJ.N) schizophrenia drug Risperdal.

The generic drugmaker is disputing that the health regulator provided legal notice that the patent had been delisted prior to Teva’s submission of a challenge to the patent.

Teva is seeking a relisiting of the patent, it said in a statement. (Reporting by Varsha Tickoo in Bangalore; Editing by Himani Sarkar)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below